ImmuneBio targets an early February 2027 UK application for Ebstracell, with potential approval by the middle of the year, and says cash will fund operations through Q3 2027.
INMB · Inmune Bio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.89
- Open
- $1.03
- Day range
- $0.89–1.03
- 52-week closing range
- $0.89–2.51
- Average volume, 30 days
- 350K
- Short interest
- 2.7M · 8.6% of shares · 14.4 days
- Short volume, last session
- 70%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern.
Inmune Bio agreed to sell 3,000,000 shares at $1.50 per share and issue unregistered warrants for up to 3,000,000 additional shares, generating expected aggregate gross proceeds of $4.5 million before fees and expenses.
INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for Ebstrocel on October 20, 2026. The company targets a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review. It also entered into a Master Services Agreement with Uniphar Durbin Ireland Limited and expects to submit a U.S. BLA in Q2 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INMB
this stock
Inmune Bio, Inc.
|
$27.68M | -42.7% | +257.1% | — | 8.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 20
INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INMB | -14.9% | -41.9% | -35.7% | -38.3% | -42.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -9.4% | -35.7% | -30.1% | -33.1% | -47.7% |